VAM
ACHN

Visium Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Visium Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-26,000
Closed -$180K – 937
2015
Q3 		$180K Buy
26,000
+2,386
+10% +$19.4K ﹤0.01% 816
2015
Q2 		$209K Sell
23,614
-2,400
-9% -$22.7K ﹤0.01% 973
2015
Q1 		$256K Sell
26,014
-23,180
-47% -$289K ﹤0.01% 851
2014
Q4 		$603K Buy
+49,194
New +$601K 0.01% 656
2014
Q1 		– Sell
-922,579
Closed -$3.06M – 1086
2013
Q4 		$3.06M Buy
+922,579
New +$2.68M 0.06% 271

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Visium Asset Management's ACHN Position: Q4 2015 in Review

Visium Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2015, closing a stake of 26,000 shares — an estimated $180K sold.

Visium Asset Management first reported a position in ACHN in Q4 2013 and held it in 5 quarters. The position peaked at $3.06M in Q4 2013. 152 funds tracked by Wall St. Rank hold ACHN as of Q4 2015.

  • Visium Asset Management reported no remaining Achillion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Visium Asset Management sold 26,000 Achillion Pharmaceuticals shares in Q4 2015, an estimated $180K.
  • Visium Asset Management first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Visium Asset Management's Achillion Pharmaceuticals position peaked at $3.06M in Q4 2013.
  • 152 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.